| Autor: |
Tsuzuki Wada T; Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan., Yokota K; Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan., Inayoshi F; Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan., Sakai S; Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan., Okumura N; Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan., Matsuda M; Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan., Osawa I; Department of Radiology, Saitama Medical University Hospital, Japan., Araki Y; Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan., Funakubo Asanuma Y; Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan., Akiyama Y; Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan., Mimura T; Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan. |
| Abstrakt: |
We present the case of a 42-year-old woman with rheumatoid arthritis and Sjögren's syndrome treated with adalimumab who developed immune-mediated necrotizing myopathy (IMNM) and trigeminal neuropathy after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination. Trigeminal neuralgia and elevated serum creatine kinase levels emerged 12 days post-vaccination, followed by myalgia in the femoral muscles. IMNM was histologically diagnosed. The pathogenesis may involve molecular mimicry between the SARS-CoV-2 spike glycoprotein and autologous tissues triggered by vaccination. This case emphasizes the association between SARS-CoV-2 vaccination, tumor necrosis factor inhibitor, IMNM, and trigeminal neuropathy, as well as the importance of monitoring immune-mediated adverse events following SARS-CoV-2 vaccination in patients with autoimmune disease. |
